Nymox Pharmaceutical Corporation (NYMXF)
Develops drugs to treat prostate cancer, Alzheimer's disease, and smoking detection tests
$0.01+0.01%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-87.5%
The outlook
NYMXF trades near its 52-week low, sitting well below both its 50- and 200-day moving averages, signaling downward momentum. Analyst coverage appears minimal or absent. The stock's current positioning reflects significant weakness over recent months.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Market cap
$954,855
52-wk high
$0.20
52-wk low
$0.01
50-day avg
$0.10
200-day avg
$0.07
Trailing P/E
—